The US-based key opinion leader (KOL) highlights that dry AMD management has evolved, with biologics like Syfovre and Izervay now providing options to slow disease progression for patients with geographic atrophy, though neither improves vision. Treatment selection is based on disease stage, lesion characteristics, and patient factors, with about 40% of patients receiving biologics and the remainder managed with observation and lifestyle changes. Izervay is increasingly preferred for new patients due to its favorable safety profile and strong commercial support, while reimbursement challenges persist for certain insurance plans. The KOL stresses the need for therapies with new mechanisms of action, greater efficacy, and improved durability, pointing to gene therapy and stem cell approaches as promising future directions. Pipeline agents are viewed with cautious optimism, pending robust Phase III data and regulatory clarity. The KOL reflects growing awareness and openness to treatment, with education and patient engagement driving increased uptake and optimism for future advances.

This interview was conducted on September 22, 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.